Skip to main content
3 December 2019
Last updated:
Tuesday 3 December 2019

User account menu

  • Log in
  • Register & Subscribe

Search this site:

 

Primary links

  • Home
  • News
  • About MedNous
  • Research Directory
  • Contact Us

Ervaxx to explore genome’s dark matter

Wednesday 6 November 2019
Country

United Kingdom

A new UK-based company has been launched to explore the dark matter of the genome with the goal of identifying antigens for the development of off-the-shelf cancer vaccines and T cell receptor based immunotherapies.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Company News
Finance, Grants, Deals

Select a News Category

  • Clinical Research
  • Company News
  • Finance, Grants, Deals
  • IPR & Legal
  • Regenerative Medicine
  • Regulation & Policy
  • Research & University News

Recent Appointments

Leonhard Stärk to advise Lysando on ethics
Monday October 7 2019
Macrophage appoints Søren Bregenholt as CEO
Monday October 7 2019
Christine Baker is CBO at Hookipa
Monday October 7 2019
Elcin Barker Ergun becomes CEO of Menarini Group
Monday October 7 2019
Jane Osbourn is chair of Mogrify board
Monday October 7 2019

© 2019 Evernow Publishing Ltd. Powered by Drupal.